

## CONTENTS

**FOREWORD** xv

**PREFACE** xvii

### PART I

**PREFORMULATION**

#### CHAPTER 1  MATHEMATICAL CONCEPTS  3

1.1 Introduction 3  
1.2 The Simple Linear Relationship 4  
1.3 Exponential Rules 7  
1.4 Logarithmic Rules 8  
1.5 Differential Equations 10  
1.6 Expanding and Reducing Formulas 12  
References 13  
Glossary 14

#### CHAPTER 2  THERMODYNAMICS  15

2.1 Introduction 15  
2.2 The Zeroth Law of Thermodynamics 15  
2.3 The First Law of Thermodynamics 16  
2.4 The Second Law of Thermodynamics 17  
2.5 The Third Law of Thermodynamics 18  
2.6 Polymorphism 18  
2.7 Physical Stability of Crystal Forms 20  
2.8 Solubility 21  
References 22  
Glossary 23

#### CHAPTER 3  SOLUBILITY AND DISSOLUTION  25

3.1 Introduction 25  
3.2 Concentration Units 26  
3.3 What Should be Done When Alcohol is Prescribed in a Formulation 35  
3.4 The Partition Coefficient 36  
3.5 Disintegration and Dissolution 38  
3.6 Concluding Remarks 43
CHAPTER 9   PARTICLE SCIENCE

9.1   Introduction  119
9.2   Particle Size Estimation and Distribution  120
9.3   Micronization  125
9.4   Particle Size Preparation and Reduction for Pulmonary Delivery  126
9.5   Polymeric Particulate Matter  128
9.6   Nanoparticles  128
9.7   Segregation of Particles  131
References  132
Glossary  133

CHAPTER 10   BASIC STATISTICS AND DESIGN OF EXPERIMENTAL CONCEPTS

10.1   Descriptive Statistics  135
10.2   Inferential Statistics  137
10.3   Statistical Applications in Quality Control Testing  146
10.4   Design of Experiment  148
References  154
Glossary  154

CHAPTER 11   FORMULATION DEVELOPMENT CONCEPTS

11.1   Preformulation  157
11.2   Scale-up Considerations  158
11.3   Combination Products  159
11.4   Rate-Controlled Drug Delivery  160
11.5   Drug Delivery Technologies for Improving Oral Delivery  163
11.6   Drug Delivery Technologies for Improving Transmucosal Delivery  165
11.7   Drug Delivery Technologies for Transdermal Delivery  166
11.8   Special Considerations for Biotechnology and Protein Delivery Systems  166
11.9   Drug–Excipient and Excipient–Excipient Interactions  170
11.10  The Presence of Contaminants in a Formulation  172
11.11  Other Considerations  173
References  174
Glossary  176

PART II   PRODUCT DESIGN

CHAPTER 12   THE PRODUCT DESIGN PROCESS

12.1   Introduction  181
12.2   Formulation Design  183
12.3   Process Design  188
12.4   Container Closure System Design  190
PART III

REGULATORY SCIENCE

CHAPTER 21 REGULATORY PRACTICES AND GUIDELINES

21.1 Worldwide Regulatory Agencies 639
21.2 Good Manufacturing Practice 651
21.3 FDA Inspection and Regulatory Actions 685
   References 687
   Glossary 689

CHAPTER 22 REGULATIONS FOR COMPOUNDING PHARMACIES

22.1 Introduction 697
22.2 Compounding Guidelines 698
22.3 FDA Compliance Policy Guides 699
22.4 Good Compounding Practices 705
22.5 Stability Criteria and Beyond-Use Dating of Compounded Preparations 717
22.6 Verification 719
22.7 Patient Counseling 719
22.8 Pharmacy Compounding Accreditation 720
   References 720
   Glossary 721
   Appendixes 722

CHAPTER 23 IND AND NDA PHASE-APPROPRIATE NEW DRUG DEVELOPMENT PROCESS

23.1 Introduction 727
23.2 Preclinical Development Overview 728
23.3 Phase-Appropriate Clinical Trials Overview 730
23.4 Investigational New Drugs 734
23.5 NDA Review Process 744
   References 750
   Glossary 751

CHAPTER 24 GENERICS, BIOSIMILARS, AND OTCS

24.1 Generic Drugs 753
24.2 Biosimilar Drugs 759
24.3 Over-the-Counter Drugs 760
   References 767
   Glossary 769
   Appendix 769
CHAPTER 25  ACCELERATED NEW DRUG APPROVAL AND EXPEDITED ACCESS OF NEW THERAPIES  

25.1  Introduction 773
25.2  Expedited Review and Approval of New Therapies 774
25.3  Expanded Access to New Therapies 776
25.4  Orphan Drugs 778
25.5  Pediatric Drugs 780
25.6  Pediatric Drug Development and the Orphan Drug Act Incentives 783
25.7  Common EMEA/FDA Application for Orphan Medicinal Product Designation 784
      References 784
      Glossary 785

CHAPTER 26  POST-DRUG APPROVAL ACTIVITIES  

26.1  Postmarket Requirements and Commitments 789
26.2  Postapproval Manufacturing Changes 790
26.3  Clinical Phase 4 Studies: Postmarketing Surveillance and Risk Assessment 792
26.4  Prescription Drug Advertising and Promotional Labeling Direct to Consumers 798
      References 799
      Glossary 801
      Appendix 804

CHAPTER 27  DRUG MASTER FILES AND EU DOSSIERS  

27.1  Drug Master Files 805
27.2  European Marketing Authorization Dossiers 817
      References 822
      Glossary 824

CHAPTER 28  COMMISSIONING AND QUALIFICATION  

28.1  Regulatory Requirements 829
28.2  Preliminary C&Q Activities 832
28.3  Commissioning 834
28.4  Qualification and Validation 838
28.5  Qualification Protocols 842
28.6  Process Validation 849
28.7  Cleaning Validation 854
28.8  Computer Systems Validation 856
28.9  Change Control 856
28.10  Revalidation 857
      References 857
      Glossary 859

CHAPTER 29  QUALITY SYSTEMS AND CONTROLS  

29.1  Pharmaceutical Quality System 863
29.2  Quality Systems Approach to CGMP Regulations 868
**CONTENTS**

29.3 Inspection of Pharmaceutical Quality Control Laboratories 875
29.4 Pharmacopeias 877
29.5 Analytical Instrument Qualification 881
29.6 Validation of Analytical Procedures 886
29.7 Stability Testing of New Drug Substances and Products 889

References 893
Glossary 895
Appendixes 900

**CHAPTER 30  SAFETY, TOXICOLOGY, AND PHARMACOGENOMICS**

30.1 Nonclinical Safety Studies 911
30.2 Safety Pharmacology Studies 914
30.3 Carcinogenicity Studies of Pharmaceuticals 918
30.4 Genotoxicity Testing 920
30.5 Immunotoxicity Studies 923
30.6 Safety Reporting Requirements 926
30.7 Pharmacogenomics 927

References 930
Glossary 932
Appendixes 935

**CHAPTER 31  REGULATORY SCIENCE INITIATIVES FOR ADVANCING PUBLIC HEALTH**

31.1 Introduction 939
31.2 Advancing Regulatory Science for Public Health: The Promise of Regulatory Science 940
31.3 Advancing Regulatory Science at FDA: Strategic Plan for Regulatory Science 940
31.4 Collaborative Implementation Framework 943

References 944
Glossary 945

**INDEX**

947